Sign in

What researchers published on Chronic myeloid leukaemia

8,372 papers, newest first.

Showing 20 of 328

  • Trial resultPopulation Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.Clinical pharmacokinetics
  • Randomised trialFive-year follow-up of OPTIC: long-term efficacy, safety, and mutation analyses of ponatinib in chronic-phase chronic myeloid leukemia from a randomized phase 2 trial.Leukemia
  • Trial resultAsciminib monotherapy in patients with BCR::ABL1 T315I-mutated chronic-phase chronic myeloid leukemia: phase 1 trial final results.Leukemia
  • Randomised trialAsciminib Provides Better Efficacy and Favorable Safety and Tolerability Against Investigator-Selected Tyrosine Kinase Inhibitors in East Asian Patients With Newly Diagnosed Chronic Myeloid Leukemia: Results From a Subgroup Analysis of the Pivotal ASC4FIRST Study.Cancer medicine
  • Trial resultEarly predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.Blood advances
  • Trial resultEffects of a High-Fat Meal on the Pharmacokinetics of Olverembatinib in Patients With Chronic Myeloid Leukemia.Clinical and translational science
  • Randomised trialFinal results of nilotinib versus nilotinib combined with pegylated interferon alfa-2a as first-line therapy in chronic phase chronic myeloid leukaemia in France (PETALs): an open-label, multicentre, randomised phase 3 trial.The Lancet. Haematology
  • Trial resultASC4OPT: asciminib treatment optimization study in patients with chronic myeloid leukemia in chronic phase previously treated with two or more tyrosine kinase inhibitors.Leukemia
  • Randomised trialClinical pharmacokinetic characteristics and the food effect of radotinib.Investigational new drugs
  • Trial resultOutcomes of Patients Treated With Dasatinib 50 mg/d: A Pooled Analysis.Clinical lymphoma, myeloma & leukemia
  • Trial resultOne-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.Annals of hematology
  • Randomised trialTreatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results.Leukemia
  • Randomised trialRandomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).Leukemia
  • Trial resultThe PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-α2b in newly diagnosed chronic phase chronic myeloid leukaemia.British journal of haematology
  • Trial resultReal-world efficacy and adverse events of frontline nilotinib in pediatric chronic myeloid leukemia in chronic phase: A prospective multicenter study from SCCCG[PLUS]-CML 2023.Cancer
  • Randomised trialAsciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.Blood
  • Randomised trialNilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint.Leukemia
  • Trial resultExposure-response analysis of asciminib efficacy and safety in patients with chronic myelogenous leukemia in chronic phase.Cancer chemotherapy and pharmacology
  • Trial resultTreatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De-Escalation: 96-Week Update of the DANTE Study.Hematological oncology
  • Trial resultSensitization of Non-M3 Acute Myeloid Leukemia Blasts to All-Trans Retinoic Acid by the LSD1 Inhibitor Tranylcypromine: TRANSATRA Phase I Study.European journal of haematology